LOGIN
Rivaroxaban offers effective extended thromboprophylaxis than enoxaparin after THA
April 2013
Rivaroxaban offers effective extended thromboprophylaxis than enoxaparin after THA
Study Type:Therapy
OE Level Evidence:1
Journal Level of Evidence:N/A
Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: A double-blind, randomised controlled trial
Lancet. 2008 Jul 5;372(9632):31-9. Epub 2008 Jun 24Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here
Synopsis
2509 patients (>18 yr old) scheduled to undergo elective total hip arthroplasty were randomized to receive either oral rivaroxaban or enoxaparin to compare both methods of thromboprophylaxis. After a 42 day follow up, extended thromboprophylaxis with rivaroxaban was significantly more effective than short-term enoxaparin plus placebo for the prevention of venous thromboembolism, including symptoma...
To view the full content, login to your account,
or start your 30-day FREE Trial today.
FREE TRIAL
LOGIN
Forgot Password?
Explore some of our unlocked ACE Reports below!
Learn about our AI Driven
High Impact Search Feature
The OE High Impact metric uses AI to determine the impact a study will have by considering the content of the article itself. Built using the latest advances of natural language processing techniques. OE High Impact predicts an article’s future number of citations than impact factor alone.
Continue
Join the Conversation
Please Login or Join to leave comments.